Tag: Drug Development
Threat to Pharmaceutical Public-Private Partnerships: Gilead’s Short-Term Win
In December 2024, a group of legal, medical, and public health experts united to file an amicus brief in support of the U.S. government...
David Epstein launches new cancer startup after Novartis and Seagen career
David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop...
Seaport Therapeutics Secures $225 Million to Advance Neuroscience Innovation in the ‘Golden Age’
Seaport Therapeutics, a new biotech startup led by the team from Karuna Therapeutics, has successfully secured an additional $225 million in funding just half...
RSV Prophylactic Beyfortus: Potential Competitors and Market Trends
Alnylam Pharmaceuticals, led by CEO Yvonne Greenstreet, is making strides in expanding the use of its RNA-based gene-silencing heart drug, vutrisiran. The drug has...
FDA Rejects MDMA and Nasal Spray for Allergic Reactions: Pharmalittle Update
Good morning everyone, hope you had a restful weekend and are ready to tackle the new week ahead. As we sip on some refreshing...
Pfizer CEO’s Vision for Leading Cancer and Obesity Treatments
Albert Bourla, the CEO of Pfizer, is looking to shift the focus of the company from its successful COVID-19 vaccine and antiviral Paxlovid to...
New Title: Soft-Tissue Cancer Drug Approval and Zepbound Shortage Update: Pharmalittle News
Good morning, this is Jonathan Wosen, reporting on the latest news in the biotech and life sciences world. The FDA has recently approved a...
BREAKING NEWS
Bluebird Bio Sold to Carlyle, SK Capital for Under $30M
Bluebird Bio, a once-promising biotech company, made headlines recently with its decision to sell itself and its portfolio of gene therapies to investment firms...
